This clinical trial is focused on studying the effects of the medication atorvastatin on individuals who experience episodic migraine. Migraines are severe headaches that can cause intense throbbing or pulsing sensations, often accompanied by nausea, vomiting, and sensitivity to light and sound. The study will use two different doses of atorvastatin, 20 mg and 40 mg, in the form of film-coated tablets, to see if it can help reduce the number of migraine days experienced by participants. A placebo, which looks like the medication but does not contain the active ingredient, will also be used for comparison.

The purpose of this study is to confirm whether atorvastatin can effectively prevent migraines, as suggested by previous smaller studies. Participants will be randomly assigned to receive either atorvastatin or a placebo. The study will last for up to 12 months, during which participants will take the medication daily. The main focus will be on observing any changes in the number of migraine days over a four-week period, comparing those taking atorvastatin to those taking the placebo.

Throughout the study, researchers will also look at the number of headache days and the number of participants who experience a significant reduction in migraine days. This trial aims to provide more information on whether atorvastatin can be a helpful treatment for people with episodic migraines, potentially offering a new option for managing this condition.